BioSpace News Archive

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need, today reported its financial results for the fourth quarter and year-ended December 31, 2019.

The National Federation of the Blind expressed its absolute opposition to any proposal in COVID-19 emergency legislation, or any other legislative or regulatory action, that would undermine the rights of blind students and other students with disabilities under the Individuals with Disabilities Education Act and other applicable laws during the crisis.

ImStem Biotechnology, Inc. announced that the U.S. Food and Drug Administration has lifted the clinical hold and cleared the Investigational New Drug application to evaluate IMS001 for the treatment of multiple sclerosis.

The Society of Chemical Manufacturers and Affiliates sent a letter to the White House and state governors reinforcing that specialty chemical manufacturers play a critical role in providing essential products to fight the COVID-19 pandemic.

Nonprofit health plan’s contribution to support urgently needed drive-through testing

GM and Ventec Life Systems, in cooperation with StopTheSpread.org, the nation’s coordinated private sector response to the COVID-19, are collaborating to enable Ventec to increase production of its respiratory care products to support the growing fight against the COVID-19 pandemic.

Biome, the leading cardiovascular performance solution provider, announces client success decreasing extended ventilator times by 44%, with no impact to patient outcomes.

The University of Mississippi Medical Center is leading an effort to address the state’s community COVID-19 outbreak by offering triage for symptoms via a new smartphone telehealth app and collection of testing samples at the Mississippi State Fairgrounds.

As the COVID-19 pandemic continues to escalate across the globe, Topcon Healthcare, a leading provider of medical devices and software solutions for the eye care community, has announced a series of initiatives and programs designed to support its customers during this time of unprecedented challenges.

Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. A